Vafidemstat (ORY-2001)
Borderline Personality Disorder (BPD)
Key Facts
About Oryzon Genomics
Oryzon Genomics is a Spanish biotech focused on developing personalized epigenetic medicines for cancer and CNS diseases. Its core achievement is building a robust clinical pipeline anchored by iadademstat, an LSD1 inhibitor in Phase II for AML, and vafidemstat for neuropsychiatric indications. The company's strategy involves expanding patent protection for key drug combinations and advancing its integrated discovery-to-early-commercialization platform to create targeted therapeutics with companion diagnostics.
View full company profileAbout Oryzon Genomics
Oryzon Genomics is a Spanish biotech focused on developing personalized epigenetic medicines for cancer and CNS diseases. Its core achievement is building a robust clinical pipeline anchored by iadademstat, an LSD1 inhibitor in Phase II for AML, and vafidemstat for neuropsychiatric indications. The company's strategy involves expanding patent protection for key drug combinations and advancing its integrated discovery-to-early-commercialization platform to create targeted therapeutics with companion diagnostics.
View full company profileAbout Oryzon Genomics
Oryzon Genomics is a Spanish biotech focused on developing personalized epigenetic medicines for cancer and CNS diseases. Its core achievement is building a robust clinical pipeline anchored by iadademstat, an LSD1 inhibitor in Phase II for AML, and vafidemstat for neuropsychiatric indications. The company's strategy involves expanding patent protection for key drug combinations and advancing its integrated discovery-to-early-commercialization platform to create targeted therapeutics with companion diagnostics.
View full company profile